5.3 Safe Administration, Handling & Infusion Toxicities
Key Takeaways
- USP <800> and NIOSH standards require personal protective equipment (PPE) including double chemotherapy-tested gloves (ASTM D6978), non-permeable gowns, and negative-pressure containment primary engineering controls (C-PEC) for handling hazardous antineoplastic drugs.
- Chemotherapy agents are classified by tissue damage potential: vesicants cause necrosis and sloughing, irritants cause local phlebitis, and flare reactions cause transient painless erythematous streaks along the vein path.
- Extravasation of DNA-binding vesicants (anthracyclines) mandates dry cold compresses to localize the drug and prompt administration of IV Dexrazoxane (Totect); non-DNA-binding vesicants (vinca alkaloids) mandate dry warm compresses and local hyaluronidase injections.
- Infusion-related hypersensitivity reactions (HSR) require immediate cessation of the infusion, patient assessment, IV normal saline flush, and administration of emergency protocols (H1/H2 blockers, corticosteroids, and IM epinephrine for anaphylaxis).
- Closed System Drug-Transfer Devices (CSTDs) must be utilized during antineoplastic compounding and administration to prevent environmental contamination and occupational exposure.
3.3 Safe Administration, Handling & Infusion Toxicities
Clinical Pearl: The management of chemotherapy extravasation depends strictly on whether the vesicant is a DNA-binding agent (e.g., anthracyclines) or a non-DNA-binding agent (e.g., vinca alkaloids). Applying heat to an anthracycline extravasation enhances tissue penetration and worsens necrosis, whereas applying cold to a vinca alkaloid extravasation worsens local tissue toxicity. Remember: Cold for Anthracyclines, Warm for Vincas!
Hazardous Drug Safe Handling & USP <800> Standards
Handling antineoplastic agents presents significant occupational exposure risks, including mutagenicity, teratogenicity, carcinogenicity, and reproductive toxicity. The National Institute for Occupational Safety and Health (NIOSH) and USP Chapter <800> establish mandatory containment and safety standards across all healthcare settings.
Personal Protective Equipment (PPE) Requirements
Healthcare personnel compounding or administering antineoplastics (NIOSH Group 1 Hazardous Drugs) must utilize specific PPE:
- Gloves: Must be tested for chemotherapy handling under ASTM D6978 standards. Powder-free gloves are required. Double gloving is mandatory: the inner glove under the gown cuff and the outer glove over the gown cuff. Outer gloves must be changed every 30 minutes or immediately if contaminated or torn.
- Gowns: Must be disposable, lint-free, non-permeable (polyethylene-coated or laminated), and close in the back (no front openings). Gowns must be changed every 2 to 3 hours or immediately following a spill.
- Respiratory & Eye Protection: Surgical N95 or NIOSH-approved respirators are required during activities generating aerosols or during spill management. Face shields or full goggles are mandatory when splash risk exists; standard prescription eyeglasses do not provide adequate eye protection.
Engineering Controls & Administration Devices
- Containment Primary Engineering Control (C-PEC): Compounding must occur in a Class II, Type B2 or C1 Biological Safety Cabinet (BSC) or Compounding Aseptic Containment Isolator (CACI) operating under negative pressure and externally vented to the outside air through HEPA filtration.
- Closed System Drug-Transfer Devices (CSTDs): CSTDs mechanically prohibit the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system. USP <800> mandates the use of CSTDs during antineoplastic administration when the dosage form allows.
Chemotherapy Extravasation Management
Extravasation is the inadvertent infiltration of a vesicant or irritant antineoplastic drug into the perivascular or subcutaneous tissue.
Tissue Damage Classification
- Vesicants: Cause severe tissue destruction, blistering, tissue necrosis, and ulceration that may require surgical excision or skin grafting (e.g., Anthracyclines, Vinca alkaloids, Mitomycin-C, Cisplatin >20 mL).
- Irritants: Cause local inflammatory changes, phlebitis, tightness, or burning along the vein path without causing tissue necrosis (e.g., Carboplatin, Etoposide, Fluorouracil, Gemcitabine).
- Exfoliants: Cause superficial tissue shedding or peeling without underlying tissue necrosis (e.g., Docetaxel, Paclitaxel).
- Flare Reactions: Localized, painless erythematous streaking along the vein path, often accompanied by urticaria, without swelling or extravasation (common with Doxorubicin). Resolves spontaneously without intervention.
Suspected Extravasation
│
├─► 1. STOP Infusion Immediately
├─► 2. Disconnect IV Tubing (DO NOT Flush Line)
├─► 3. Aspirate Residual Drug with Syringe (3-5 mL)
├─► 4. Remove Peripheral Cannula / Elevate Extremity
│
├─► Classify Vesicant Type
│ │
│ ├─► DNA-Binding (Anthracyclines) ──► Apply COLD Compress + IV Dexrazoxane
│ │
│ └─► Non-DNA-Binding (Vinca Alkaloids) ─► Apply WARM Compress + SubQ Hyaluronidase
Specific Extravasation Antidote & Thermal Management Protocol
| Vesicant Class | Representative Agents | Thermal Application | Pharmacologic Antidote & Administration |
|---|---|---|---|
| DNA-Binding Vesicants | Doxorubicin, Epirubicin, Daunorubicin, Idarubicin | Dry COLD Compress (15–20 min QID for 48 hrs) to cause vasoconstriction and localize drug | Dexrazoxane (Totect): Systemic IV infusion given over 1–2 hours for 3 consecutive days. Must initiate within 6 hours of extravasation. Day 1: 1000 mg/m²; Day 2: 1000 mg/m²; Day 3: 500 mg/m². Alternatives: Topical DMSO (99%). |
| Non-DNA-Binding Vesicants | Vincristine, Vinblastine, Vinorelbine (etoposide is an irritant with vesicant potential, managed with the same warm-compress and hyaluronidase approach) | Dry WARM Compress (15–20 min QID for 48 hrs) to cause vasodilation and drug dispersion | Hyaluronidase: Subcutaneous injections into extravasation site. Inject 150–300 units SC divided into 4–5 clockwise injections around the site using a 25-gauge needle. |
| Platinum Compounds | Cisplatin (concentrated >0.5 mg/mL or volume >20 mL) | Dry COLD Compress | Sodium Thiosulfate: 1/6 Molar (1.67%) solution. Inject 2–3 mL SC through existing catheter or percutaneously around the extravasation site. |
Infusion-Related Reactions (IRR) & Hypersensitivity
Infusion-related toxicities range from mild flushing to life-threatening anaphylaxis.
Pathophysiologic Mechanisms
- Type I IgE-Mediated Anaphylaxis: True allergic sensitization requiring prior exposure. Mediated by IgE cross-linking on mast cells/basophils, releasing histamine and leukotrienes. Classically seen with Platinum agents (Carboplatin, Oxaliplatin) occurring after multiple cycles (typically cycle 6 to 8).
- Non-IgE Cytokine Release / Complement Activation (CARPA): Pseudo-allergic reaction occurring during the first or second infusion without prior sensitization. Mediated by massive cytokine release or complement cascade activation. Classically seen with Taxanes (Paclitaxel due to Cremophor EL) and Monoclonal Antibodies (Rituximab).
Emergency Management of Acute Hypersensitivity (CTCAE v5.0 Grade 3–4)
Acute Hypersensitivity / Anaphylaxis Onset
│
├─► 1. IMMEDIATELY STOP Infusion
├─► 2. Call for Emergency Assistance & Assess Airway, Breathing, Circulation (ABCs)
├─► 3. Disconnect Infusion Tubing; Maintain IV Access with 0.9% Normal Saline
├─► 4. Administer Supplemental Oxygen (100% via non-rebreather mask)
├─► 5. Elevate Patient's Legs (if hypotensive)
│
▼ Emergency Pharmacotherapy
├─► Epinephrine (1:1000 / 1 mg/mL): 0.3 to 0.5 mg IM into anterolateral thigh (repeat Q5-15 min)
├─► Diphenhydramine: 50 mg IV push
├─► Famotidine: 20 mg IV push
├─► Methylprednisolone: 1 to 2 mg/kg IV push
└─► IV Fluid Bolus: 1 to 2 Liters 0.9% Normal Saline for persistent hypotension
An oncology nurse practitioner is called to evaluate a patient undergoing peripheral IV administration of doxorubicin. The patient complains of severe burning pain at the IV insertion site. Upon inspection, the APRN notes swelling, erythema, and drug extravasation. After stopping the infusion, aspirating drug residual, and removing the IV catheter, which thermal application and antidote combination is indicated?
Under USP Chapter <800> guidelines for handling hazardous antineoplastic drugs, which statement regarding Personal Protective Equipment (PPE) and administration devices is CORRECT?
A patient with non-small cell lung cancer receiving their 7th cycle of carboplatin suddenly develops acute dyspnea, generalized hives, facial edema, and a blood pressure of 82/46 mmHg ten minutes into the infusion. What is the APRN's IMMEDIATE priority action?